Physician profile
Eric J Lewis
NPI 1467465518
$1,057.85
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $238 · 2020: $45.63 · 2021: $214 · 2022: $123 · 2023: $104 · 2024: $334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $437.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $437.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $220.47 | 2021-2024 | Opzelura |
| Janssen Biotech, INC. | $119.22 | 2019-2024 | Tremfya |
| Novartis Pharmaceuticals Corporation | $113.02 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $110.22 | 2024 | Sotyktu |
| Ucb, INC. | $96.96 | 2021-2024 | Bimzelx |
| Celgene Corporation | $65.10 | 2019 | |
| Leo Pharma INC. | $64.40 | 2023 | Adbry |
| Stemline Therapeutics INC. | $57.11 | 2021 | |
| Regeneron Pharmaceuticals, INC. | $45.00 | 2019 | |
| Dusa Pharmaceuticals, INC. | $39.99 | 2019 | |
| Lilly USA, LLC | $25.99 | 2022 | |
| Genzyme Corporation | $24.25 | 2021-2022 | |
| Portola Pharmaceuticals, LLC | $15.87 | 2019 | |
| Sun Pharmaceutical Industries INC. | $14.49 | 2019 | |
| Merck Sharp & Dohme LLC | $12.62 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $11.20 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.14 | 2019 | |
| Pfizer INC. | $10.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.